Pinto Serge, Cardoso Rita, Sadat Jasmin, Guimarães Isabel, Mercier Céline, Santos Helena, Atkinson-Clement Cyril, Carvalho Joana, Welby Pauline, Oliveira Pedro, D'Imperio Mariapaola, Frota Sónia, Letanneux Alban, Vigario Marina, Cruz Marisa, Martins Isabel Pavão, Viallet François, Ferreira Joaquim J
Aix Marseille Université, Centre National de la Recherche Scientifique (CNRS), Laboratoire Parole et Langage (LPL), Aix-en-Provence, France.
Brain and Language Research Institute, Aix-en-Provence, France.
BMJ Open. 2016 Nov 17;6(11):e012885. doi: 10.1136/bmjopen-2016-012885.
Individuals with Parkinson's disease (PD) have to deal with several aspects of voice and speech decline and thus alteration of communication ability during the course of the disease. Among these communication impairments, 3 major challenges include: (1) dysarthria, consisting of orofacial motor dysfunction and dysprosody, which is linked to the neurodegenerative processes; (2) effects of the pharmacological treatment, which vary according to the disease stage; and (3) particular speech modifications that may be language-specific, that is, dependent on the language spoken by the patients. The main objective of the FraLusoPark project is to provide a thorough evaluation of changes in PD speech as a result of pharmacological treatment and disease duration in 2 different languages (French vs European Portuguese).
Individuals with PD are enrolled in the study in France (N=60) and Portugal (N=60). Their global motor disability and orofacial motor functions is assessed with specific clinical rating scales, without (OFF) and with (ON) pharmacological treatment. 2 groups of 60 healthy age-matched volunteers provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks are recorded to obtain acoustic and perceptual measures. Patient-reported outcome measures are used to assess the psychosocial impact of dysarthria on quality of life.
The study has been approved by the local responsible committees on human experimentation and is conducted in accordance with the ethical standards. A valuable large-scale database of speech recordings and metadata from patients with PD in France and Portugal will be constructed. Results will be disseminated in several articles in peer-reviewed journals and in conference presentations. Recommendations on how to assess speech and voice disorders in individuals with PD to monitor the progression and management of symptoms will be provided.
NCT02753192, Pre-results.
帕金森病（PD）患者在疾病过程中必须应对语音和言语衰退的多个方面，从而导致沟通能力改变。在这些沟通障碍中，三大主要挑战包括：（1）构音障碍，由口面部运动功能障碍和言语韵律障碍组成，与神经退行性过程有关；（2）药物治疗的效果，其因疾病阶段而异；（3）可能因语言而异的特定言语改变，即取决于患者所讲的语言。FraLusoPark项目的主要目标是全面评估在两种不同语言（法语与欧洲葡萄牙语）中，药物治疗和疾病持续时间对帕金森病患者言语变化的影响。
法国（N = 60）和葡萄牙（N = 60）的帕金森病患者参与该研究。使用特定临床评定量表评估他们在未进行药物治疗（关期）和进行药物治疗（开期）时的整体运动残疾和口面部运动功能。两组各60名年龄匹配的健康志愿者作为组间比较的参照。除临床检查外，还记录多项言语任务以获取声学和感知测量数据。采用患者报告结局测量方法评估构音障碍对生活质量的心理社会影响。
该研究已获得当地人类实验责任委员会的批准，并按照伦理标准进行。将构建一个包含法国和葡萄牙帕金森病患者语音记录和元数据的宝贵大规模数据库。研究结果将在同行评审期刊的多篇文章以及会议报告中发表。将提供有关如何评估帕金森病患者言语和语音障碍以监测症状进展和管理的建议。
NCT02753192，预结果。
